No abstract available
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alanine / adverse effects
-
Alanine / analogs & derivatives
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / genetics
-
Alzheimer Disease / metabolism*
-
Alzheimer Disease / physiopathology
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors
-
Amyloid Precursor Protein Secretases / metabolism
-
Amyloid beta-Peptides / antagonists & inhibitors
-
Amyloid beta-Peptides / genetics
-
Amyloid beta-Peptides / immunology
-
Amyloid beta-Peptides / metabolism
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Azepines / adverse effects
-
Clinical Trials as Topic
-
Disease Progression
-
Genetic Therapy
-
Glycogen Synthase Kinase 3 / antagonists & inhibitors
-
Glycogen Synthase Kinase 3 / metabolism
-
Humans
-
Indoles / pharmacology
-
Indoles / therapeutic use
-
Memantine / pharmacology
-
Memantine / therapeutic use
-
Methylene Blue / therapeutic use
-
Molecular Targeted Therapy* / statistics & numerical data
-
Molecular Targeted Therapy* / trends
-
Nerve Growth Factor / genetics
-
Nerve Growth Factor / therapeutic use
-
Neurofibrillary Tangles / drug effects
-
Phosphorylation
-
tau Proteins / chemistry
-
tau Proteins / metabolism
Substances
-
Amyloid beta-Peptides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Azepines
-
Indoles
-
N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
-
tau Proteins
-
Nerve Growth Factor
-
Glycogen Synthase Kinase 3
-
Amyloid Precursor Protein Secretases
-
bapineuzumab
-
latrepirdine
-
Alanine
-
Methylene Blue
-
Memantine